Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study

Kazuro Iwai, Kenzo Soejima, Shoji Kudoh, Yoshimasa Umezato, Toru Kaneko, Kouji Yoshimori, Hitoshi Tokuda, Tetsuo Yamaguchi, Akira Mizoo, Yasuhiro Setoguchi, Takashi Kamigaki, Katsunada Fujimoto, Shigenori Goto

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose To clarify the long-term effect of immunotherapy, the effect of adoptive activated T lymphocyte immunotherapy on advanced lung cancer was evaluated in terms of survival time. In addition, the performance status of cancer patients under immunotherapy was examined. Experimental design Over 5×109 alpha-beta T lymphocytes cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2 were injected intravenously into patients, once every 2 weeks for 3 months or longer. Follow- up of these patients was carried out using clinical records and by telephone interview questionnaire. Patients undergoing immunotherapy in immunotherapy clinics and those undergoing other anticancer therapies without immunotherapy in seven hospitals in Tokyo were enrolled in this study. Data were analyzed by a third-party statistician. Performance status was studied on another series of various cancer patients who underwent immunotherapy. Results The overall median survival time of the patients with the best supportive care, which was obtained using Kaplan-Meier's model, was 5.6 months, and those with immunotherapy alone, chemotherapy alone, and immuno-chemotherapy were 12.5, 15.7, and 20.8 months, respectively. Using Cox' proportional hazard model, we examined the possible factors on survival time by univariate analysis. Then, the patients were stratified by gender and histological type for multivariate analysis. Significantly low hazard ratios were observed for immunotherapy and radiotherapy in males with squamous cancer; for chemotherapy and radiotherapy in males with adenocarcinoma; and for immunotherapy in females with adenocarcinoma. Addition of immunotherapy to chemotherapy resulted in a statistically significant decrease in hazard ratio in females with adenocarcinoma. Studies on the performance status (PS), determined according to the European Cooperative Oncology Group criteria, revealed a continuous high level of PS under immunotherapy until around 2 months before death, in contrast to the gradual increase of tumor marker level. Conclusions The effectiveness of immunotherapy on advanced lung cancer is limited but may extend life span under certain conditions. Immunotherapy itself provided no clinical benefit by itself as compared with chemotherapy, but a significant additive effect of immunotherapy on chemotherapy was observed in females with adenocarcinoma. Moreover, immunotherapy can maintain good quality of life of the patients until near the time of death.

Original languageEnglish
Pages (from-to)1781-1790
Number of pages10
JournalCancer Immunology, Immunotherapy
Volume61
Issue number10
DOIs
Publication statusPublished - 2012 Oct

Fingerprint

Immunotherapy
Lung Neoplasms
Cohort Studies
T-Lymphocytes
Survival
Drug Therapy
Adenocarcinoma
Radiotherapy
Immobilized Antibodies
Adoptive Immunotherapy
Neoplasms
Tokyo
Tumor Biomarkers
Proportional Hazards Models
Interleukin-2
Anti-Idiotypic Antibodies
Research Design
Multivariate Analysis
Quality of Life

Keywords

  • Additive effect
  • Adoptive immunotherapy
  • Advanced lung cancer
  • Overall survival
  • Performance status
  • T lymphocyte

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer : Results of a multicenter historical cohort study. / Iwai, Kazuro; Soejima, Kenzo; Kudoh, Shoji; Umezato, Yoshimasa; Kaneko, Toru; Yoshimori, Kouji; Tokuda, Hitoshi; Yamaguchi, Tetsuo; Mizoo, Akira; Setoguchi, Yasuhiro; Kamigaki, Takashi; Fujimoto, Katsunada; Goto, Shigenori.

In: Cancer Immunology, Immunotherapy, Vol. 61, No. 10, 10.2012, p. 1781-1790.

Research output: Contribution to journalArticle

Iwai, K, Soejima, K, Kudoh, S, Umezato, Y, Kaneko, T, Yoshimori, K, Tokuda, H, Yamaguchi, T, Mizoo, A, Setoguchi, Y, Kamigaki, T, Fujimoto, K & Goto, S 2012, 'Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study', Cancer Immunology, Immunotherapy, vol. 61, no. 10, pp. 1781-1790. https://doi.org/10.1007/s00262-012-1226-4
Iwai, Kazuro ; Soejima, Kenzo ; Kudoh, Shoji ; Umezato, Yoshimasa ; Kaneko, Toru ; Yoshimori, Kouji ; Tokuda, Hitoshi ; Yamaguchi, Tetsuo ; Mizoo, Akira ; Setoguchi, Yasuhiro ; Kamigaki, Takashi ; Fujimoto, Katsunada ; Goto, Shigenori. / Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer : Results of a multicenter historical cohort study. In: Cancer Immunology, Immunotherapy. 2012 ; Vol. 61, No. 10. pp. 1781-1790.
@article{d4ed31f198784a549f875d4f0b4dcedf,
title = "Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: Results of a multicenter historical cohort study",
abstract = "Purpose To clarify the long-term effect of immunotherapy, the effect of adoptive activated T lymphocyte immunotherapy on advanced lung cancer was evaluated in terms of survival time. In addition, the performance status of cancer patients under immunotherapy was examined. Experimental design Over 5×109 alpha-beta T lymphocytes cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2 were injected intravenously into patients, once every 2 weeks for 3 months or longer. Follow- up of these patients was carried out using clinical records and by telephone interview questionnaire. Patients undergoing immunotherapy in immunotherapy clinics and those undergoing other anticancer therapies without immunotherapy in seven hospitals in Tokyo were enrolled in this study. Data were analyzed by a third-party statistician. Performance status was studied on another series of various cancer patients who underwent immunotherapy. Results The overall median survival time of the patients with the best supportive care, which was obtained using Kaplan-Meier's model, was 5.6 months, and those with immunotherapy alone, chemotherapy alone, and immuno-chemotherapy were 12.5, 15.7, and 20.8 months, respectively. Using Cox' proportional hazard model, we examined the possible factors on survival time by univariate analysis. Then, the patients were stratified by gender and histological type for multivariate analysis. Significantly low hazard ratios were observed for immunotherapy and radiotherapy in males with squamous cancer; for chemotherapy and radiotherapy in males with adenocarcinoma; and for immunotherapy in females with adenocarcinoma. Addition of immunotherapy to chemotherapy resulted in a statistically significant decrease in hazard ratio in females with adenocarcinoma. Studies on the performance status (PS), determined according to the European Cooperative Oncology Group criteria, revealed a continuous high level of PS under immunotherapy until around 2 months before death, in contrast to the gradual increase of tumor marker level. Conclusions The effectiveness of immunotherapy on advanced lung cancer is limited but may extend life span under certain conditions. Immunotherapy itself provided no clinical benefit by itself as compared with chemotherapy, but a significant additive effect of immunotherapy on chemotherapy was observed in females with adenocarcinoma. Moreover, immunotherapy can maintain good quality of life of the patients until near the time of death.",
keywords = "Additive effect, Adoptive immunotherapy, Advanced lung cancer, Overall survival, Performance status, T lymphocyte",
author = "Kazuro Iwai and Kenzo Soejima and Shoji Kudoh and Yoshimasa Umezato and Toru Kaneko and Kouji Yoshimori and Hitoshi Tokuda and Tetsuo Yamaguchi and Akira Mizoo and Yasuhiro Setoguchi and Takashi Kamigaki and Katsunada Fujimoto and Shigenori Goto",
year = "2012",
month = "10",
doi = "10.1007/s00262-012-1226-4",
language = "English",
volume = "61",
pages = "1781--1790",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "10",

}

TY - JOUR

T1 - Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer

T2 - Results of a multicenter historical cohort study

AU - Iwai, Kazuro

AU - Soejima, Kenzo

AU - Kudoh, Shoji

AU - Umezato, Yoshimasa

AU - Kaneko, Toru

AU - Yoshimori, Kouji

AU - Tokuda, Hitoshi

AU - Yamaguchi, Tetsuo

AU - Mizoo, Akira

AU - Setoguchi, Yasuhiro

AU - Kamigaki, Takashi

AU - Fujimoto, Katsunada

AU - Goto, Shigenori

PY - 2012/10

Y1 - 2012/10

N2 - Purpose To clarify the long-term effect of immunotherapy, the effect of adoptive activated T lymphocyte immunotherapy on advanced lung cancer was evaluated in terms of survival time. In addition, the performance status of cancer patients under immunotherapy was examined. Experimental design Over 5×109 alpha-beta T lymphocytes cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2 were injected intravenously into patients, once every 2 weeks for 3 months or longer. Follow- up of these patients was carried out using clinical records and by telephone interview questionnaire. Patients undergoing immunotherapy in immunotherapy clinics and those undergoing other anticancer therapies without immunotherapy in seven hospitals in Tokyo were enrolled in this study. Data were analyzed by a third-party statistician. Performance status was studied on another series of various cancer patients who underwent immunotherapy. Results The overall median survival time of the patients with the best supportive care, which was obtained using Kaplan-Meier's model, was 5.6 months, and those with immunotherapy alone, chemotherapy alone, and immuno-chemotherapy were 12.5, 15.7, and 20.8 months, respectively. Using Cox' proportional hazard model, we examined the possible factors on survival time by univariate analysis. Then, the patients were stratified by gender and histological type for multivariate analysis. Significantly low hazard ratios were observed for immunotherapy and radiotherapy in males with squamous cancer; for chemotherapy and radiotherapy in males with adenocarcinoma; and for immunotherapy in females with adenocarcinoma. Addition of immunotherapy to chemotherapy resulted in a statistically significant decrease in hazard ratio in females with adenocarcinoma. Studies on the performance status (PS), determined according to the European Cooperative Oncology Group criteria, revealed a continuous high level of PS under immunotherapy until around 2 months before death, in contrast to the gradual increase of tumor marker level. Conclusions The effectiveness of immunotherapy on advanced lung cancer is limited but may extend life span under certain conditions. Immunotherapy itself provided no clinical benefit by itself as compared with chemotherapy, but a significant additive effect of immunotherapy on chemotherapy was observed in females with adenocarcinoma. Moreover, immunotherapy can maintain good quality of life of the patients until near the time of death.

AB - Purpose To clarify the long-term effect of immunotherapy, the effect of adoptive activated T lymphocyte immunotherapy on advanced lung cancer was evaluated in terms of survival time. In addition, the performance status of cancer patients under immunotherapy was examined. Experimental design Over 5×109 alpha-beta T lymphocytes cultured ex vivo with an immobilized anti-CD3 antibody and interleukin-2 were injected intravenously into patients, once every 2 weeks for 3 months or longer. Follow- up of these patients was carried out using clinical records and by telephone interview questionnaire. Patients undergoing immunotherapy in immunotherapy clinics and those undergoing other anticancer therapies without immunotherapy in seven hospitals in Tokyo were enrolled in this study. Data were analyzed by a third-party statistician. Performance status was studied on another series of various cancer patients who underwent immunotherapy. Results The overall median survival time of the patients with the best supportive care, which was obtained using Kaplan-Meier's model, was 5.6 months, and those with immunotherapy alone, chemotherapy alone, and immuno-chemotherapy were 12.5, 15.7, and 20.8 months, respectively. Using Cox' proportional hazard model, we examined the possible factors on survival time by univariate analysis. Then, the patients were stratified by gender and histological type for multivariate analysis. Significantly low hazard ratios were observed for immunotherapy and radiotherapy in males with squamous cancer; for chemotherapy and radiotherapy in males with adenocarcinoma; and for immunotherapy in females with adenocarcinoma. Addition of immunotherapy to chemotherapy resulted in a statistically significant decrease in hazard ratio in females with adenocarcinoma. Studies on the performance status (PS), determined according to the European Cooperative Oncology Group criteria, revealed a continuous high level of PS under immunotherapy until around 2 months before death, in contrast to the gradual increase of tumor marker level. Conclusions The effectiveness of immunotherapy on advanced lung cancer is limited but may extend life span under certain conditions. Immunotherapy itself provided no clinical benefit by itself as compared with chemotherapy, but a significant additive effect of immunotherapy on chemotherapy was observed in females with adenocarcinoma. Moreover, immunotherapy can maintain good quality of life of the patients until near the time of death.

KW - Additive effect

KW - Adoptive immunotherapy

KW - Advanced lung cancer

KW - Overall survival

KW - Performance status

KW - T lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=84867573369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867573369&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1226-4

DO - 10.1007/s00262-012-1226-4

M3 - Article

C2 - 22422103

AN - SCOPUS:84867573369

VL - 61

SP - 1781

EP - 1790

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 10

ER -